VRS
LGND icon

Virginia Retirement Systems’s Ligand Pharmaceuticals LGND Stock Holding History

Virginia Retirement Systems’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$284K Buy
+1,500
New +$288K ﹤0.01% 860
2020
Q3 		– Sell
-11,061
Closed -$772K – 1133
2020
Q2 		$772K Sell
11,061
-4,168
-27% -$264K 0.01% 668
2020
Q1 		$691K Sell
15,229
-5,129
-25% -$291K 0.01% 682
2019
Q4 		$1.32M Buy
20,358
+3,526
+21% +$236K 0.01% 580
2019
Q3 		$1.04M Buy
16,832
+1,764
+12% +$111K 0.01% 676
2019
Q2 		$1.07M Buy
15,068
+481
+3% +$35.4K 0.01% 654
2019
Q1 		$1.14M Buy
14,587
+1,923
+15% +$146K 0.01% 627
2018
Q4 		$1.07M Buy
12,664
+481
+4% +$51.3K 0.01% 596
2018
Q3 		$2.09M Sell
12,183
-1,603
-12% -$242K 0.02% 459
2018
Q2 		$1.78M Sell
13,786
-2,404
-15% -$268K 0.02% 479
2018
Q1 		$1.67M Buy
16,190
+10,419
+181% +$1.03M 0.02% 503
2017
Q4 		$493K Buy
+5,771
New +$500K 0.01% 813
2017
Q3 		– Sell
-6,733
Closed -$510K – 1075
2017
Q2 		$510K Sell
6,733
-17,312
-72% -$1.21M 0.01% 832
2017
Q1 		$1.59M Buy
24,045
+1,282
+6% +$84.3K 0.02% 532
2016
Q4 		$1.44M Buy
22,763
+2,084
+10% +$132K 0.02% 490
2016
Q3 		$1.32M Buy
20,679
+481
+2% +$35.3K 0.02% 496
2016
Q2 		$1.5M Buy
+20,198
New +$1.5M 0.02% 445
2015
Q4 		$1.52M Sell
22,442
-802
-3% -$49.5K 0.02% 428
2015
Q3 		$1.24M Sell
23,244
-3,686
-14% -$224K 0.02% 461
2015
Q2 		$1.7M Sell
26,930
-4,809
-15% -$262K 0.03% 391
2015
Q1 		$1.53M Sell
31,739
-4,008
-11% -$154K 0.02% 427
2014
Q4 		$1.19M Buy
35,747
+7,214
+25% +$235K 0.02% 469
2014
Q3 		$836K Buy
+28,533
New +$947K 0.01% 561
2014
Q2 		– Sell
-8,496
Closed -$357K – 981
2014
Q1 		$357K Buy
8,496
+1,603
+23% +$66.8K 0.01% 746
2013
Q4 		$226K Sell
6,893
-26,930
-80% -$877K ﹤0.01% 802
2013
Q3 		$913K Sell
33,823
-1,924
-5% -$54.1K 0.02% 489
2013
Q2 		$834K Buy
+35,747
New +$643K 0.02% 514

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Virginia Retirement Systems's LGND Position: Q4 2025 in Review

Virginia Retirement Systems opened a new position in Ligand Pharmaceuticals (LGND) in Q4 2025: 1,500 shares worth $284K. The stake represents ﹤0.01% of the portfolio and ranks #860 among its holdings. This is a return to the name: Virginia Retirement Systems previously reported a position in LGND as recently as Q2 2020.

Virginia Retirement Systems first reported a position in LGND in Q2 2013 and has held it in 27 quarters since. The position peaked at $2.09M in Q3 2018. 349 funds tracked by Wall St. Rank hold LGND as of Q4 2025.

  • Virginia Retirement Systems held 1,500 shares of Ligand Pharmaceuticals worth $284K as of Q4 2025.
  • Ligand Pharmaceuticals was a new Virginia Retirement Systems position in Q4 2025.
  • Ligand Pharmaceuticals made up ﹤0.01% of Virginia Retirement Systems's portfolio in Q4 2025, its #860 holding.
  • Virginia Retirement Systems first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 27 quarters since.
  • Virginia Retirement Systems's Ligand Pharmaceuticals position peaked at $2.09M in Q3 2018.
  • 349 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2025.

Based on Virginia Retirement Systems's 13F filing for Q4 2025, filed 4 Feb 2026.